Obsidian Therapeutics
Obsidian Therapeutics is a clinical-stage biotechnology company developing engineered cell and gene therapies. Their lead program, OBX-115, is a novel engineered tumor-infiltrating lymphocyte (TIL) cell therapy designed to improve the treatment of advanced or metastatic melanoma and other solid tumors. The company utilizes its proprietary cytoDRiVE® technology for precise regulation of protein function.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $160.5M
Date: 03-Apr-2024
Investors: Wellington Management, Foresite Capital, Janus Henderson Investors, Novo Holdings A/S, Paradigm BioCapital, RTW Investments, T. Rowe Price, Woodline Partners LP, Atlas Venture, Blue Owl Healthcare Opportunities, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCGX, Samsara BioCapital, Surveyor Capital
Markets: Biotechnology, Cell Therapy, Gene Therapy, Oncology, Health Care, Pharmaceutical
HQ: Cambridge, Massachusetts, United States
Founded: 2015
Website: https://www.obsidiantx.com/
LinkedIn: https://www.linkedin.com/company/obsidian-therapeutics/
Twitter: https://twitter.com/obsidian_tx
Crunchbase: https://www.crunchbase.com/organization/obsidian-therapeutics
Leave a Comment
Comments
No comments yet.